Pricing Log in Create free account
Saturday 17 October 2026 Export GRDX’s income statement to Excel — free account

GridAI Technologies Corp.

GRDX Healthcare Biotechnology

GridAI Technologies Corp.’s revenue for fiscal 2025 (year ended December 2025) was $36,300.00. In the quarter to June 2026, EPS fell 219.0%, free cash flow fell 2,641.0% and total debt fell 64.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

4.22 0.24 −5.38%
Market cap
$31.8M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−6.58
Beneish M
n/a
Dividend safety
n/a
Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 5.28%

Capital & Financial Ratios $m

Market Cap 31.81
Revenue —
Net Income (20.77)
Free Cash Flow (8.12)
Net Debt (1.13)
Current Ratio 0.16 (below 1: weak)
Debt/Equity 0.01 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 0.00
P/B ratio 1.82
Past 5Y EPS Growth —
This Y EPS Growth 97.30% (at or above 15%: strong)
Next Y EPS Growth (34.51%) (below 0%: weak)
Next Y revenue growth —
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 41.66%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 4 0 1 1
Receivables — — 1 0
Inventory — — — —
Other — 83 0 —
5 83 3 2
2023 2024 2025 Q'26
Payables 1 3 3 2
ST’ Debt — 23 0 0
Other 0 0 6 6
3 28 15 14

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 119.08%

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (1) 0 (1) (4) (6)
’24 (4) (3) (2) 0 (9)
’23 (3) (3) (3) (3) (12)
’22 (8) (5) (4) (6) (22)
’21 (5) (6) (16) (6) (32)
’20 (1) (1) (3) (6) (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (1) 0 (1) (4) (6)
’24 (4) (3) (2) 0 (9)
’23 (3) (3) (3) (3) (12)
’22 (8) (5) (4) (6) (22)
’21 (5) (6) (16) (6) (32)
’20 (1) (1) (3) (6) (11)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.82) (2.01) — — —
’25 (0.84) (0.63) (0.75) (2.35) (4.05)
’24 1.14 (11.58) (1.77) (3.70) (15.99)
’23 (109.21) (113.41) (27.60) 104.14 (143.65)
’22 (8.32k) (3.15k) 1.09k (568.26) (1.26k)
’21 (17.65k) (20.18k) (41.23k) (9.16k) (119.42k)
’20 (0.20) (0.17) (59.27k) (39.09k) (145.02k)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 495,180.00 302,400.00 126,000.00 52,416.00 46,746.00 16,002.00 180.60 8.25 0.56 0.97

Analyst estimates 2026–2028

Powerpack
High 705,600.00 661,500.00 514,080.00 390,600.00 244,188.00 331,380.00 21,105.00 537.60 28.05 5.84
People
People Employees 8 13 12 10 12 17 10 9 2 2
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02
Income, $m
Income, $m Revenue — — — — — — — — — 0
Gross margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — — (1,811.02)
EBT (15) (11) (14) (15) (33) (59) (15) (16) (16) (7)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (18,292.01)
Net income (15) (11) (14) (15) (33) (59) (15) (16) (18) (7)
Depreciation 1 1 1 1 1 3 0 0 0 1
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02
Earnings (2.24) (1.04) (0.88) (0.68) (145,016.00) (119,415.70) (1,260.13) (143.65) (15.99) (2.81)
Cash flow (0.70) (0.68) (0.70) (0.63) (56,107.50) (46,126.00) (1,862.01) (110.42) (8.05) (3.53)
Capex 0.00 0.00 (0.02) 0.00 437.00 (99.29) 0.00 0.00 0.00 0.00
Free cash flow (0.70) (0.68) (0.72) (0.63) (55,670.50) (46,225.29) (1,862.01) (110.42) (8.05) (3.53)
Book value 0.49 0.16 0.29 0.21 (13,203.50) (11,173.71) 228.52 32.14 50.48 17.83
Shares, m 7 11 15 22 0 0 0 0 1 2
Valuation, ×
Valuation, × P/E — — — — — — — — — 0.00
P/S — — — — — — — — — 0.00
P/B — — — — — — — — — 0.30
EV/Sales — — — — — — — — — 0.00
EV/FCF — — — — — — — — — (2.34)
Cash, $m
Cash, $m Operating cash flow (5) (7) (11) (14) (11) (32) (22) (12) (9) (6)
Capex 0 0 0 0 0 0 — — — —
Free cash flow (5) (7) (11) (14) (11) (32) (22) (12) (9) (6)
Balance, $m
Balance, $m Working capital 1 (1) 2 (1) (8) (3) 1 2 56 (13)
Total debt 0 0 0 1 1 1 1 — 23 0
Net debt (2) 0 (1) 1 (5) (8) (1) (4) 23 (1)
Shareholders’ equity 3 2 4 5 (3) (8) 3 4 58 29
Returns, %
Returns, % ROA (217.15) (181.41) (209.03) (185.41) (382.40) (683.98) (173.81) (261.35) (39.66) (10.05)
ROIC (247.90) (475.14) (232.25) (166.99) 0.00 0.00 (386.73) 0.00 (12.12) (15.70)
ROE 749.10 (455.37) (441.23) (333.90) (4,222.85) 1,615.68 589.55 (507.58) 13,367.64 (63.89)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Oct 2026

Charts ten years each

GridAI Technologies Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ALGS Aligos Therapeutics, Inc. $33.7M — (loss-making) — (loss-making) +2,778.55% (above 0%: growing) n/m −59.81% (below 0%: shrinking) 100.00% (6.80%) Compare
ATNM Actinium Pharmaceuticals, Inc. $33.3M 3.1× — (loss-making) +77,677.78% (above 0%: growing) n/m −4.91% (below 0%: shrinking) 100.00% 78.76% Compare
BCTX BRIACELL THERAP $32.8M 1.5× — — n/m +0.21% (above 0%: growing) 0.00% 0.00% Compare
GNTA Genenta Science S.p.A. Unsponsored ADR $32.3M — — — — +35.94% (above 0%: growing) 0.00% — Compare
MGX Metagenomi Therapeutics, Inc. $31.9M — (loss-making) — (loss-making) −103.02% (below 0%: shrinking) n/m +7.98% (above 0%: growing) 100.00% 11,195.72% Compare
GRDX GridAI Technologies Corp. $31.8M — (loss-making) — — n/m −2,640.98% (below 0%: shrinking) (42.49%) (15,258.21%)
NXTC NextCure, Inc. $31.5M — (loss-making) — (loss-making) +1,549.08% (above 0%: growing) n/m +57.23% (above 0%: growing) 0.00% 0.00% Compare
CVM Cel-Sci Corporation $30.6M — (loss-making) — (loss-making) −62.66% (below 0%: shrinking) n/m −2.33% (below 0%: shrinking) 0.00% 0.00% Compare
RNAZ TransCode Therapeutics Inc. $30.5M — (loss-making) — — n/m −28.79% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $32.1M — — +1,549.08% — −1.06% 0.00% 0.00%

All 614 Biotechnology stocks →

GridAI Technologies Corp. (GRDX) key facts

  • GridAI Technologies Corp. (GRDX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • GridAI Technologies Corp.’s revenue for fiscal 2025 (year ended December 2025) was $36,300.00.
  • As of October 16, 2026, GRDX traded at $4.22, a market capitalization of $31.8 million.
  • Return on equity was −63.9% and debt-to-equity 0.01.
  • Its Altman Z-score is −6.58 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.

GridAI Technologies Corp. (GRDX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/GRDX · Data as of Oct 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com